{
    "clinical_study": {
        "@rank": "146453", 
        "arm_group": [
            {
                "arm_group_label": "Immediate release capsule", 
                "arm_group_type": "Active Comparator", 
                "description": "Immediate release capsule treatment under fasted condition"
            }, 
            {
                "arm_group_label": "sustained release tablet", 
                "arm_group_type": "Experimental", 
                "description": "sustained release tablet treatment under fasted condition"
            }, 
            {
                "arm_group_label": "sustained release tablet (high fat meal)", 
                "arm_group_type": "Experimental", 
                "description": "sustained release tablet under high fat meal condition."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to:\n\n        1. Compare the pharmacokinetics profiles of pregabalin sustained release tablet (300mg) to\n           immediate release capsule(150mg * 2).\n\n        2. Evaluate the effectiveness of food to pharmacokinetics profile of Pregabalin sustained\n           release tablet."
        }, 
        "brief_title": "Study for Comparing The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg With Immediate Release Formulation and to Assess the Effect of High Fat Diet in Healthy Male Subjects", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Neuropathic Pain", 
        "condition_browse": {
            "mesh_term": "Neuralgia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  19~44 aged healthy adult.\n\n          -  someone tho has at least 50kg body weight and ideal body weight \u00b120%\n\n        Exclusion Criteria:\n\n          -  someone has acute symptom at screening phase\n\n          -  someone has any disease or symptoms which is clinically significant\n\n          -  someone had been determined during healthy examination in screening period\n\n          -  AST or ALT >  1.25 times than normal\n\n          -  Total bilirubin > 1.5 times than normal\n\n          -  someone who has a history of allergy, anaphylaxis, drug abuse or misuse.\n\n          -  someone who had enrolled to other clinical trial within the last 60 days.\n\n          -  someone who had donated blood within the last 60 days.\n\n          -  someone who can't take a meal derived from this trial.\n\n          -  someone who has taken abnormal meals like which can affect to drug ADME\n\n          -  someone who has taken other ETC drugs or oriental drugs within the last 14 days, Or\n             OTC drugs within the last 7 days\n\n          -  someone who has taken caffein continuously (coffee or green tea more than 5 cups per\n             a day) or took caffein since 24hours before.\n\n          -  someone who has taken alcohol more than 30g/day or smoked more than 10 piece of\n             tobacco/day.\n\n          -  someone who has galactose intolerance, Lapp lactase deficiency or glucose-galactose\n             malabsorption."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "44 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02103686", 
            "org_study_id": "ID-PRSD-1201"
        }, 
        "intervention": [
            {
                "arm_group_label": "Immediate release capsule", 
                "intervention_name": "Lyrica", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "sustained release tablet", 
                    "sustained release tablet (high fat meal)"
                ], 
                "description": "sustained release formulation of pregabalin", 
                "intervention_name": "Experimental drug", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "sustained release tablet (high fat meal)", 
                "intervention_name": "High fat meal", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": [
                    "Immediate release capsule", 
                    "sustained release tablet"
                ], 
                "intervention_name": "fasted", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Pregabalin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Neuropathic pain", 
            "pregabalin"
        ], 
        "lastchanged_date": "April 1, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Open-label, 3-way Crossover Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg With Immediate Release Formulation and to Assess the Effect of High Fat Diet in Healthy Male Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Cmax, AUC of pregabalin", 
            "safety_issue": "No", 
            "time_frame": "0~36h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02103686"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety evaluation", 
            "safety_issue": "Yes", 
            "time_frame": "0~24day"
        }, 
        "source": "IlDong Pharmaceutical Co Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "IlDong Pharmaceutical Co Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}